Drug Trial Radar · NCT04709575
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
Last checked: Nov 19, 2026Latest source record: Oct 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
353
Actual
Start
Jan 14, 2021
Primary completion
Aug 24, 2021
Study completion Aug 24, 2021
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.
Conditions
- Allergic Rhinitis
- Conjunctivitis
Interventions
REGN5713Drug
Administered subcutaneously
REGN5714Drug
Administered subcutaneously
REGN5715Drug
Administered subcutaneously
PlaceboDrug
Placebo that replaces REGN5713-5714-5715
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus PlaceboTime frame: Until the end of Birch Pollen Season, up to Week 16
Locations
37 sites in 5 countries. Site status is shown where the registry gives one.
Regeneron Study Site
Bangor, Maine
Regeneron Study Site
Baltimore, Maryland
Regeneron Study Site
Plymouth, Minnesota
Regeneron Study Site
Columbia, Missouri
Regeneron Study Site
St Louis, Missouri
Regeneron Study Site
Missoula, Montana
Regeneron Study Site
Verona, New Jersey
Regeneron Study Site
Great Neck, New York
Regeneron Study Site
Cincinnati, Ohio
Regeneron Study Site
Toledo, Ohio
Regeneron Study Site
Portland, Oregon
Regeneron Study Site
Pittsburgh, Pennsylvania
Regeneron Study Site
Lincoln, Rhode Island
Regeneron Study Site
Greenfield, Wisconsin
Regeneron Study Site
Ghent, Oost-Vlaanderen, Belgium
Regeneron Study Site
Leuven, Vlaams Brabant, Belgium
Regeneron Study Site
Québec, Canada
Regeneron Study Site
Kingston, Ontario, Canada
Regeneron Study Site
London, Ontario, Canada
Regeneron Study Site
Ottawa, Ontario, Canada
Regeneron Study Site
Toronto, Ontario, Canada
Regeneron Study Site
Toronto, Ontario, Canada
Regeneron Study Site
Toronto, Ontario, Canada
Regeneron Study Site
Trois-Rivières, Quebec, Canada
Regeneron Study Site
Hvidovre, Capital, Denmark
Regeneron Study Site
Hellerup, Copenhagen Surroundings, Denmark
Regeneron Study Site
Vejle, South Jutland, Denmark
Regeneron Study Site
Berlin, Germany
Regeneron Study Site
Berlin, Germany
Regeneron Study Site
Hamburg, Germany
Regeneron Study Site
Heidelberg, Baden-Wurttemberg, Germany
Regeneron Study Site
Stuttgart, Baden-Wurttemberg, Germany
Regeneron Study Site
Dreieich, Hesse, Germany
Regeneron Study Site
Wiesbaden, Hesse, Germany
Regeneron Study Site
Duisburg, North Rhine-Westphalia, Germany
Regeneron Study Site
Düsseldorf, North Rhine-Westphalia, Germany
Regeneron Study Site
Dresden, Saxony, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.